Sponsored Gilead Sciences Raises $1B In Note Sale Gilead Sciences has raised $1 billion in a sale of senior unsecured floating-rate notes. March 24, 2011
Sponsored Gilead To Buy Pharmasset For $11B Biopharmaceutical company Gilead Sciences will be acquiring clinical-stage pharmaceutical company Pharmasset. November 22, 2011
This content is from: Portfolio Gilead Sciences’ Miracle Drug Combination Investors stand to benefit from Gilead’s top-selling hepatitis C and HIV drugs even as the biotech company is trading at a discount. By Vitaliy Katsenelson February 23, 2016
This content is from: Corner Office Short Sellers Hurt by Gilead’s Kite Acquisition Kite Pharma has likely been a target for bearish bets because the cancer-fighting technology it uses — CART — is new to the market, says Wedbush biotechnology analyst David Nierengarten. By Alicia McElhaney August 28, 2017
This content is from: Premium One of the Best-Performing Hedge Funds in Recent Years Just Got Richer Why Avoro Capital Advisors cheered Gilead’s deal to acquire Immunomedics. By Stephen Taub September 16, 2020
This content is from: Research The 2013 All-America Research Team: Biotechnology, No. 2: Geoffrey Meacham In second place for a sixth year running is Geoffrey Meacham of J.P. Morgan. October 08, 2013
